Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties

被引:59
|
作者
Ulrich, Silvia
Fischler, Manuel
Speich, Rudolf
Popov, Vladimir
Maggiorini, Marco
机构
[1] Univ Zurich Hosp, Dept Internal Med, Div Resp, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Dept Internal Med, Div Crit Care Med, CH-8091 Zurich, Switzerland
[3] Clin Pulm Med & Rehabil, Barmelweid, Switzerland
关键词
chronic thromboembolic pulmonary hypertension; pulmonary arterial hypertension; pulmonary hemodynamics; pulmonary vascular compliance; vasoreactivity testing;
D O I
10.1378/chest.130.3.841
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are the major classes of pulmonary hypertensive disorders according to the World Health Organization; both lead to right heart failure and death. A better understanding of disease mechanisms has led to the suggestion that the thromboembolic and nonthrombo-embolic types of pulmonary hypertension may share pathophysiologic features. We therefore compared acute vasoreactivity and proximal pulmonary artery compliance in patients with PAH and CTEPH during the initial diagnostic heart catheterization. Methods: Right heart catheterization using a flow-directed Swan-Ganz catheter was performed in patients with CTEPH (n = 22) and PAH (n = 35). Pulmonary hemodynamics were assessed at baseline, during the inhalation of 40 ppm of nitric oxide, and 30 min after the inhalation of 10 mu g of iloprost. To assess the proximal pulmonary artery compliance, the pulse pressure (PP) [systolic - diastolic pressure] and the fractional PIP (PPf) [divided by the mean pressure] were calculated. Results: Both vasodilators produced similar hemodynamic improvement, and the difference between CTEPH and PAH was not significant. The baseline PP and PPf did not vary between the two groups. Conclusion: Patients with PAH and CTEPH show similar acute vasoreactivity to inhaled nitric oxide and iloprost, and have similar pulmonary artery compliance. These findings support the presence of some shared pathophysiologic pathways in both disorders and may lead to therapeutic implications in patients with inoperable CTEPH.
引用
收藏
页码:841 / 846
页数:6
相关论文
共 50 条
  • [41] Invasive pulmonary artery pulsatility index in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    Marinho, A.
    Baptista, R.
    Castro, G.
    Monteiro, P.
    Providencia, L. A.
    EUROPEAN HEART JOURNAL, 2010, 31 : 628 - 628
  • [42] Body fluid status in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    Yogeswaran, A.
    Husain-Seyed, F.
    Tello, K.
    Sommer, N.
    Rako, Z. A.
    Ghofrani, H. A.
    Seeger, W.
    Richter, M. J.
    Gall, H.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1910 - 1910
  • [43] Idiopathic Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension: Can We Be Certain?
    Berger, Gidon
    Azzam, Zaher S.
    Hardak, Emilia
    Tavor, Yonit
    Yigla, Mordechai
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2011, 13 (02): : 106 - 110
  • [44] Anxiety and depression disorders in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    Dominik Harzheim
    Hans Klose
    Fabiola Peña Pinado
    Nicola Ehlken
    Christian Nagel
    Christine Fischer
    Ardeschir Ghofrani
    Stephan Rosenkranz
    Hans-Jürgen Seyfarth
    Michael Halank
    Eckhard Mayer
    Ekkehard Grünig
    Stefan Guth
    Respiratory Research, 14
  • [45] CXCL13 in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
    Olsson, Karen M.
    Olle, Sandra
    Fuge, Jan
    Welte, Tobias
    Hoeper, Marius M.
    Lerch, Christian
    Maegel, Lavinia
    Haller, Hermann
    Jonigk, Danny
    Schiffer, Lena
    RESPIRATORY RESEARCH, 2016, 17
  • [46] Riociguat: A Novel Therapeutic Option for Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Mielniczuk, Lisa M.
    Swiston, John R.
    Mehta, Sanjay
    CANADIAN JOURNAL OF CARDIOLOGY, 2014, 30 (10) : 1233 - 1240
  • [47] Developments in pulmonary arterial hypertension-targeted therapy for chronic thromboembolic pulmonary hypertension
    Hadinnapola, Charaka
    Pepke-Zaba, Joanna
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (05) : 559 - 569
  • [48] Pulmonary Artery Compliance in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: The Pulmonary Hypertension Association Registry
    McCormick, A.
    Krishnan, A.
    Badesch, D. B.
    Benza, R.
    Bull, T. M.
    De Marco, T.
    Feldman, J. P.
    Hemnes, A.
    Hirsch, R.
    Horn, E.
    Kennedy, J.
    Mathai, S. C.
    McConnell, J. W.
    Pugliese, S.
    Sager, J. S.
    Shlobin, O. A.
    Simon, M.
    Lammi, M. R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [49] Rapid Titration of Riociguat in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Katta, S.
    Safdar, Z.
    Sahay, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [50] Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study
    Ghofrani, H. A.
    Hoeper, M. M.
    Halank, M.
    Meyer, F. J.
    Staehler, G.
    Behr, J.
    Ewert, R.
    Weimann, G.
    Grimminger, F.
    EUROPEAN RESPIRATORY JOURNAL, 2010, 36 (04) : 792 - 799